Tag Archive for: age-related macular degeneration (AMD)

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

/in

Investigating potential for an oral treatment in diabetic retinopathy First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, […]

Read more

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

/in

Industry expert Ulrik Mouritzen M.D. appointed Chief Executive Officer Funding to advance lead asset to phase 1b clinical trial and further build pipeline COPENHAGEN, Denmark, Nov. 10, 2022 /PRNewswire/ — Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR […]

Read more

DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

/in

Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company […]

Read more